Literature DB >> 17554034

Universal and mutation-resistant anti-enteroviral activity: potency of small interfering RNA complementary to the conserved cis-acting replication element within the enterovirus coding region.

Hui Sun Lee1,2, Jeonghyun Ahn1,2, Youngmee Jee3, Il Sun Seo1,2, Eun Jung Jeon1,2, Eun-Seok Jeon4,5, Chul Hyun Joo1,2, Yoo Kyum Kim1,2, Heuiran Lee1,2.   

Abstract

The promising potential of RNA interference-based antiviral therapies has been well established. However, the antiviral efficacy is largely limited by genomic diversity and genetic instability of various viruses, including human enterovirus B (HEB). In this work, the first evidence supporting the anti-HEB activity of the small interfering RNA (siRNA) targeting the highly conserved cis-acting replication element (CRE) within virus coding region 2C is presented. HeLa cells pre-treated with siRNA complementary to the conserved sequence of the loop region of CRE(2C) were effectively rescued from the cytopathic effects of HEBs. Downregulation of virus replication and attenuation of cytotoxicity were consistently observed in various reference strains and clinical isolates. Cells treated with this siRNA were resistant to the emergence of viable escape mutants and showed sustained antiviral ability. Collectively, the data suggest that the siRNA based on the disordered structure within the highly conserved cis-acting coding region has potential as a universal, persistent anti-HEB agent. The same strategy can be successfully applied to the development of siRNA with consistent antiviral effects in other virus groups possessing similar RNA elements.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554034     DOI: 10.1099/vir.0.82633-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Design of small interfering RNAs for antiviral applications.

Authors:  Diana Rothe; Erik J Wade; Jens Kurreck
Journal:  Methods Mol Biol       Date:  2011

2.  Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model.

Authors:  Yeon-Jung Kim; Jeonghyun Ahn; Soo-Young Jeung; Dae-Sun Kim; Ha-Na Na; Young-Joo Cho; Soo-Hyeon Yun; Youngmee Jee; Eun-Seok Jeon; Heuiran Lee; Jae-Hwan Nam
Journal:  Virus Genes       Date:  2008-01-03       Impact factor: 2.332

3.  Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin.

Authors:  Jeonghyun Ahn; Ha-Na Woo; Ara Ko; Maria Khim; Catherine Kim; Nung Hwa Park; Ho-Young Song; Seong Who Kim; Heuiran Lee
Journal:  Cell Mol Life Sci       Date:  2012-05-05       Impact factor: 9.261

4.  Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA.

Authors:  Xin Ye; Zhen Liu; Maged Gomaa Hemida; Decheng Yang
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

5.  Inhibition of coxsackievirus infection in cardiomyocytes by small dsRNA targeting its cognate coxsackievirus adenovirus receptor.

Authors:  Mirnalini Sharma; Baijayantimala Mishra; Uma Nahar Saikia; Ajay Bahl; R K Ratho
Journal:  Indian J Med Res       Date:  2017-10       Impact factor: 2.375

Review 6.  Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.

Authors:  Henry Fechner; Sandra Pinkert; Anja Geisler; Wolfgang Poller; Jens Kurreck
Journal:  Molecules       Date:  2011-10-11       Impact factor: 4.411

Review 7.  A review on current status of antiviral siRNA.

Authors:  Abid Qureshi; Vaqar Gani Tantray; Altaf Rehman Kirmani; Abdul Ghani Ahangar
Journal:  Rev Med Virol       Date:  2018-04-15       Impact factor: 6.989

Review 8.  RNA interference: from basic research to therapeutic applications.

Authors:  Jens Kurreck
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.